

Index

Note: page numbers in *italics* refer to figures and tables

- abetalipoproteinemia 205
- aceruloplasminemia 249–50
- acute disseminated encephalomyelitis (ADEM) 259
- adenosine triphosphate (ATP), Parkinson’s disease 234
- akinesia in Parkinson’s disease 89
- Alexander disease 256, 258
- Alzheimer’s disease
 - biomarkers of disease progression 264
 - gray matter atrophy 156
 - iron sequestration in substantia nigra 21
 - myo*-inositol 232
 - premotor cortex atrophy 154
- amygdala
 - cognitive impairment in
 - Parkinson’s disease 49
 - Gilles de la Tourette syndrome 124
- anti-NMDA receptor antibody encephalopathy 260
- antipsychotic therapy, Gilles de la Tourette syndrome 124
- apathy in Parkinson’s disease 73–4
 - resting-state fMRI 89–90
- apparent diffusion coefficient (ADC)
 - Friedreich’s ataxia 207
 - Huntington’s disease 111
 - multiple system atrophy 179–80
- aprataxin (*APT*X) gene 209–10
- argyrophilic grain disease 162
- arterial spin labeling (ASL), Parkinson’s disease 268
- ascorbate, Parkinson’s disease 233
- ataxia 204–23, 256–9
 - acquired 259
 - acute disseminated encephalomyelitis 259
 - autosomal dominant
 - spinocerebellar 213–23, 214
 - myo*-inositol 232
 - autosomal recessive with known gene mutation 204–12, 205
 - hereditary 256–8
 - multiple sclerosis 259
 - POLG* gene mutations 256–8
 - X-linked 212–13
 - see also* cerebellar ataxia
 - ataxia with oculomotor apraxia
 - type 1 (AOA1) 205, 209–10, 210
 - type 2 (AOA2) 205, 210, 210–11
 - ataxia telangiectasia 205, 208–9
 - cerebellar atrophy 209
 - corticosteroid treatment 209
 - diagnosis 209
 - fMRI 209
 - MRS 209
 - white matter lesions 209
 - ataxia with isolated vitamin E deficit (AVED) 205, 211
 - ataxin 1 gene 213
 - ataxin 2 gene 217
 - ataxin 7 gene 221
 - ATM* gene 208–9
 - attention-deficit hyperactivity disorder (ADHD) 122
 - auditory network (AUN) 85
 - autosomal dominant spinocerebellar ataxias *see* spinocerebellar ataxias, autosomal dominant
 - autosomal recessive ataxia with known gene mutation 204–12, 205
 - autosomal recessive ataxia with oculomotor apraxia (AOA) 205, 209–11
 - autosomal recessive cerebellar ataxia 205
 - axial mean diffusivity in multiple system atrophy 195
 - Parkinson variant (MSA-P) 188
- basal ganglia
 - calcification 246–8, 247
 - copper deposition 250
 - dystonia 134, 136, 139, 141
 - fiber pathways 101
 - Gilles de la Tourette syndrome 124
 - iron deposition 248–50, 249
 - manganese deposition 251
 - metal deposition 246–51
 - molybdenum deposition 251
 - organization 78
 - Parkinson’s disease 170, 233
 - processing 73–4
 - spinocerebellar ataxia 1 213–16
 - spinocerebellar ataxia 3 219
 - toxoplasmosis lesion 262
 - see also* globus pallidus (GP); striatum
- biofeedback training, Parkinson’s disease 69
- biomarkers
 - disease progression 264
 - Huntington’s disease 106, 111
 - Parkinson’s disease
 - resting-state fMRI 90
 - surrogate 1
- blepharospasm, dystonia 134, 136, 137, 139, 144
- BOLD (blood oxygen level-dependent) signal
 - Huntington’s disease 111–12
 - Parkinson’s disease 8, 31
 - complex hand movements 62
 - fMRI 74
 - outcome measures 266
 - resting state 84
 - sequential finger movements 65
 - supplementary motor area 57–60, 64, 68–9
 - treatment effects 68–9
- botulinum toxin, dystonia 134, 136
- bradykinesia, Parkinson’s disease 66
- brain atrophy
 - corticobasal degeneration 155
 - familial *MAPT* mutations 159–60
 - fragile X tremor/ataxia syndrome 212
 - Huntington’s disease 108–9
 - MAPT* gene mutations 159
 - multiple system atrophy 194, 194–5
 - Parkinson variant (MSA-P) 192
 - Parkinson’s disease 194
 - progressive supranuclear palsy 194
 - spinocerebellar ataxia 6 219–20
 - see also* named regions of brain
- brainstem
 - essential tremor 240
 - Parkinson’s disease 170, 229

Index

- brainstem (cont.)
 - progressive supranuclear palsy syndrome 150
- brainstem atrophy
 - corticobasal degeneration 158
 - fragile X tremor/ataxia syndrome 213
 - progressive supranuclear palsy 158, 253
 - spinocerebellar ataxia 1 213–16
 - spinocerebellar ataxia 3 219
- calcium
 - basal ganglia effects 246–8, 247
 - Fahr syndrome 248
- caudate nucleus
 - Gilles de la Tourette syndrome 124, 129
 - Huntington's disease 255
- central autonomic degeneration, multiple system atrophy 168–9
- cerebellar ataxia 204
 - ataxia with oculomotor apraxia type 1 209
 - autosomal recessive 205
 - multiple system atrophy differential diagnosis 179
- cerebellar atrophy
 - ataxia with oculomotor apraxia type 1 210
 - type 2 210
 - ataxia telangiectasia 209
 - ataxia with isolated vitamin E deficit 211
 - isolated 258
 - multiple system atrophy 190
 - spinocerebellar ataxia 1 213–16
 - spinocerebellar ataxia 2 217–18
 - see also* pontocerebellar atrophy
- cerebellar peduncle *see* middle cerebellar peduncle atrophy; superior cerebellar peduncle
- cerebellar–cerebral connection
 - disruption, spinocerebellar ataxia 17 223
- cerebellum
 - connectivity in dystonia 143
 - essential tremor origin 238–40, 243
 - function 204
 - hypoperfusion in ataxia with oculomotor apraxia type 1 210
 - neurodegeneration in
 - spinocerebellar ataxia 17 223
 - volume
 - loss in Friedreich's ataxia 207
 - Parkinson's disease 48
- cerebral blood flow (CBF), Huntington's disease 112
- cerebral metabolic rate of ATP (CMR_{ATP}) 8
- cerebral metabolic rate of oxygen (CMRO₂) 8
- cerebrotendinous xanthomatosis (CTX) 205, 211–12
- ceruloplasmin 15
- chenodeoxycholic acid 212
- choline (Cho)
 - ataxia telangiectasia 209
 - multiple system atrophy 193
 - Parkinson's disease 231
 - progressive supranuclear palsy syndrome 153
- chorea 253–5
 - bilateral 253–5
 - Huntington's disease 253
 - post-infective 253
- clinical applications of neuroimaging 246–61
 - ataxia 256–9
 - dystonia 255–6
 - extrapyramidal disorders 252–6
 - infective conditions 260–1
 - metal deposition affecting basal ganglia 246–51
 - normal/non-specific abnormalities 246
 - post-infective disorders 261
- clinical trials 264–8
 - clinical ratings 264
 - databases for multicenter imaging studies of Parkinson's disease 268
 - intraoperative MRI 268
 - outcome measures 264–5
 - potential MRI measures 265–7
- cognition in Parkinson's disease
 - fMRI 72–9
 - resting-state fMRI 89–90
- cognitive impairment
 - cerebrotendinous xanthomatosis 212
 - default mode network markers 88
 - dementia with Lewy bodies 44
 - Friedreich's ataxia 207–8
 - Parkinson's disease 44–51, 72
 - age effects 49
 - amygdala 49
 - cognitive measure correlation 47
 - cognitive spectrum 46
 - cortical atrophy 46, 50
 - cortico-striatal network function 74–6
 - deactivated brain regions 79
 - default mode network 79
 - entorhinal cortex 49, 52
 - global MRI measures 48
 - hippocampal volume 48–9
 - hippocampus 79
 - longitudinal studies 49–50
 - overmedication hypothesis 76
 - resting-state fMRI 89–90
 - substantia innominata 49
 - treated patients 46
 - white matter changes 51
- Parkinson's disease with dementia 44
- congenital disorder of glycosylation type 1A 205
- copper, basal ganglia deposition 250
- corpus callosum
 - Gilles de la Tourette syndrome 124
 - multiple system atrophy 195
- cortex
 - atrophy
 - corticobasal syndrome 154, 157, 255
 - fragile X tremor/ataxia syndrome 213
 - frontal 247
 - Parkinson's disease 46, 50
 - Pick's disease 162
 - progressive supranuclear palsy syndrome 151–2, 157
 - Gilles de la Tourette syndrome 124, 128
 - thickness 125, 127
 - tic severity correlation 124
- Parkinson's disease
 - atrophy 46, 50
 - dopamine deficiency effects 75
 - hyperactivation 66
 - lesions 34–5
 - thickness 28–9, 45, 47–8
- thickness
 - cognitive impairment 47–8
 - Gilles de la Tourette syndrome 125, 127
 - Huntington's disease 109
 - measurement in Parkinson's disease 28–9, 45, 47–8
- cortex, Gilles de la Tourette syndrome 128
- corticobasal degeneration (CBD) 147–8
 - atrophy distribution 149
 - brain atrophy 155
 - brainstem atrophy 158
 - cortical atrophy 255
 - diffusion tensor imaging 154–5
 - dopamine transporter imaging 156
 - gray matter atrophy 154, 156, 157
 - imaging in pathologically confirmed 157–8
 - MRS 155
 - nuclear medicine 155–6, 156
 - pathological characteristics 148

Index

- PET 155–6, 156
SPECT 155–6
white matter atrophy 154
white matter tract degeneration 154–5
- cortico-basal ganglia circuits, Gilles de la Tourette syndrome 129
- corticobasal syndrome (CBS) 147–8
cortical atrophy 154, 255
frontotemporal lobar degeneration 156
premotor cortex atrophy 154
structural MRI 154
- corticosteroids, ataxia telangiectasia treatment 209
- cortico-striatal system, Parkinson's disease 72–3
cognitive impairment 74–6
dopaminergic medication 89
incentive salience 77–8
motivation disorders 76–9
reward processing 77
risk-taking 78
- cortico-striato-pallido-thalamo-cortical circuit model, Parkinson's disease 88
- cortico-striato-thalamo-cortical loops
Gilles de la Tourette syndrome 124
dysfunction 122–4, 129
tic expression 128
network anatomical organization 123
- creatine (Cr)
ataxia telangiectasia 209
corticobasal degeneration 155
essential tremor 240–1
familial *MAPT* mutations 160
multiple system atrophy 193
Parkinson's disease 231
progressive supranuclear palsy syndrome 153
- creatine and phosphocreatine (tCr)
Huntington's disease 113, 115–16
Parkinson's disease 231
- Creutzfeldt–Jakob disease 259, 261
variant 261
- CYP27A1* gene 211
- Dandy Walker syndrome 247–8, 248
- deep brain stimulation (DBS) surgery 94–103
consensus target coordinates 97
frame-based stereotaxy 96
frameless stereotaxy 96
internal globus pallidus 95
consensus target coordinates 97, 97
- dystonia 95
MRI sequences for visualization 97
- MRI-compatible devices 103
- Parkinson's disease 8, 19–20
fMRI 69
internal globus pallidus 95
subthalamic nucleus 9, 19–20, 95
- perioperative imaging 96
- 7T MRI platforms 98, 100–2
- subthalamic nucleus
consensus target coordinates 97, 97
MRI sequences for visualization 97
- Parkinson's disease 9, 19–20, 95
- targeting
atlas diagrams 97
brain shift 97–9
direct 97–9
high-field MRI 100–2
indirect 97–9
intraoperative MRI 99–100
microelectrode recording 99
problems 99–100
stereotactic system accuracy 99
technique 96
- targets 94
location variability 99
movement disorder treatment 95–6
- tremor 95–6
- ventral intermediate nucleus
consensus target coordinates 97, 97
MRI sequences for visualization 97
- tremor 95–6
- default mode network (DMN)
anatomy 85
cognitive ability marker 88
connectivity in familial *MAPT* mutations 160–1
Parkinson's disease 79
task performance 90
- deformation-based morphometry (DBM), Parkinson's disease 45, 48
- dementia
biomarkers of disease progression 264
Parkinson's disease 44, 72, 252
tangle-dominant 163–4
- dementia with Lewy bodies (DLB) 44, 252
cognitive impairment 44
cortical atrophy 48
hippocampal volume 48–9
- dentate nucleus
cerebrotendinous xanthomatosis 212
iron deposition 248–9
Refsum's disease 211
- dentatorubrothalamic tract
connectivity 154
- depression in Parkinson's disease 35
resting-state fMRI 89–90
- diffusion imaging
dystonia 142–4
Huntington's disease 111
Parkinson's disease 32, 36–8, 45
- diffusion tensor imaging (DTI)
corticobasal degeneration 154–5
essential tremor 241
familial *MAPT* mutations 160
Friedreich's ataxia 207
Gilles de la Tourette syndrome 124, 126
human connectome project 8
Huntington's disease 111
multiple system atrophy 190–1
Parkinson's disease 7–8, 30, 36–8, 45
cognitive impairment 51
iron levels 17, 18
outcome measures 265–6
progressive supranuclear palsy syndrome 152–3
substantia nigra 266
tauopathies 149
- diffusion-weighted imaging (DWI)
essential tremor 241
Friedreich's ataxia 207
Huntington's disease 111
multiple system atrophy 170, 179–88, 190–1, 195–6
diagnostic accuracy 181
Parkinson's disease 30, 36–8, 45
- dopamine
deficiency in Parkinson's disease 72–4
cortical activation 75
fMRI 267
reward-based learning 77
role 73–4
- dopamine system, functional neuroanatomy 73–4
- dopamine transporter imaging
cerebrotendinous xanthomatosis 212
corticobasal degeneration 156
essential tremor 242
familial *MAPT* mutations 161–2
Parkinson's disease 242
progressive supranuclear palsy syndrome 153
spinocerebellar ataxia 2 218

Index

- dopaminergic medication
fMRI 267
Parkinson's disease
 BOLD signal effects 68–9
 cortico-striatal connectivity 89
 overmedication hypothesis 76
 resting-state fMRI 89
 reward-based learning 77
dopaminergic nigrostriatal neurons 73
essential tremor 242
Parkinson's disease 233
 degeneration 232
 essential tremor distinction 242
 loss 57
 nuclear imaging 264
dopaminergic transmission, Gilles de la Tourette syndrome 124, 129
dynamic Bayesian networks (DBN) 86–7
dystonia 134–44, 255–6
 action-induced 134, 136
 basal ganglia
 activation 136, 139, 141
 inhibitory control deficiency 134
 blepharospasm 134, 136, 137, 139, 144
 botulinum toxin 134, 136
 cerebellar connectivity 143
 craniocervical 134, 136
 deep brain stimulation of internal globus pallidus 95
 definition 134
 diffusion imaging 142–4
 embouchure 134, 137–8, 138
 fiber tract integrity 143
 fMRI 135, 136, 138
 during sensory stimulation 138–41
 focal 134
 craniocervical 136
 hand 134–5, 135, 136, 144
 motor activation studies 134–5
 fractional anisotropy 142–4
 functional connectivity 141
 gray matter density 141–2
 hand 134–5, 135, 136, 144
 hereditary 255
 hypoxic brain injury 257
 internal globus pallidus deep brain stimulation 95
 laryngeal 134, 136–7, 138, 144
 mean diffusibility 143–4
 motor activation studies 134–8
 musician's 134, 135, 137–8, 138
 orofacial 136, 137, 139
 POLG gene mutations 256–8
 primary 255
 resting-state fMRI 141
 secondary 255–6
 somatosensory system 138–41
 voxel-based morphometry 141–2, 144
 white matter lesions 143–4
 writer's cramp 134, 139, 140, 142
embouchure dystonia 134, 137–8, 138
encephalitis lethargica
 see postencephalitic parkinsonism (PEP)
entorhinal cortex, cognitive impairment in Parkinson's disease 49, 52
essential tremor 238–43
 brainstem 240
 cerebellum 238–40, 243
 diffusion tensor imaging 241
 diffusion-weighted imaging 241
 dopamine transport dysfunction 242–3
 dopamine transporter imaging 242
 dopaminergic nigrostriatal neuron preservation 242
 ethanol effects 240
 fMRI 240
 fractional anisotropy 241
 glucose metabolism 240
 ¹H MRS 240
 inferior olivary nucleus 239–40, 259
 MRS 240–1
 neurodegeneration 240–2
 neuroimaging 241–2
 Parkinson's disease differential diagnosis 242–3
 pathophysiology 238, 243
 PET 239–40
 voxel-based morphometry 241
 ethanol, essential tremor 240
 executive control network 85
 executive dysfunction, Parkinson's disease 72, 74–6
 executive function, executive control network 85
 extrapyramidal disorders 252–6
 eye of the tiger sign 249–50, 250
face of the giant panda/panda cub 250, 251
Fahr syndrome 247, 248
familial FTD dementia and parkinsonism linked to chromosome 17 (FTDP-17) 148
familial *MAPT* mutations
 brain atrophy 159–60
 diffusion tensor imaging 160
 MRS 160
 nuclear medicine 161
 pathological characteristics 148
 resting-state fMRI 160–1, 161
 structural MRI 158–60
 white matter tract degeneration 160
 see also microtubule-associated protein tau (*MAPT*) gene mutations
fatty acid hydroxylase-associated neurodegeneration (FAHN) 249–50
ferritin
 brain content 14
 Parkinson's disease 15–16
 sequestration in brain 15
fluid-attenuated inversion recovery (FLAIR), Parkinson's disease 45
fractional anisotropy (FA)
 cerebrotendinous xanthomatosis 212
 dystonia 142–4
 essential tremor 241
 Huntington's disease 111
 multiple system atrophy 180–7, 191
 Parkinson's disease 7, 7, 11, 45
 cognitive impairment 51
 iron levels 17
 outcome measures 265–6
 spinocerebellar ataxia 7 223
fragile X tremor/ataxia syndrome (FXTAS) 212–13
fraxatin gene 204
freezing of gait, Parkinson's disease 35, 67–8
 resting-state fMRI 89
Friedreich's ataxia 204–8, 205, 208
 apparent diffusion coefficient 207
 cognitive impairment 207–8
 diffusion tensor imaging 207
 diffusion-weighted imaging 207
 MRS 207
 mutation 204
 neuropathology 204–7
 spinal cord atrophy 207
 superior cerebellar peduncle changes 207
 voxel-based morphometry 207
frontoparietal network (FPN) 85
frontostriatal syndrome, Parkinson's disease 72
frontotemporal dementia 148
 behavioral variant 148, 160
frontotemporal lobar degeneration (FTLD)
 corticobasal syndrome 156
 premotor cortex atrophy 154
functional connectivity assessment, Parkinson's disease 31, 35

Index

- functional connectivity map (fcMAP) 86
- functional magnetic resonance imaging (fMRI)
- ataxia telangiectasia 209
 - dopamine role 267
 - dopaminergic medication 267
 - dystonia 135, 136, 138, 138–41
 - essential tremor 240
 - Huntington's disease 111–12
 - Parkinson's disease 57–69
 - cognition and mood 72–9
 - complex hand movements 62–5
 - deep brain stimulation 69
 - hand movement correlates 57–62
 - methods 74
 - motor symptom correlates 65–8
 - outcome measures 266–7
 - see also* resting-state fMRI (rs-fMRI)
 - FXN* allele 204
 - FXTAS* gene 212
- GABA, Parkinson's disease 232–3
- GABAergic pathways, Parkinson's disease 232
- gait *see* freezing of gait
- gene vector delivery, Parkinson's disease 268
- Gilles de la Tourette syndrome 121–30
- antipsychotic therapy 124
 - basal ganglia 124
 - behavioral disorders 122
 - brain abnormality mapping 124–9
 - caudate nucleus 129
 - clinical aspects 121–2
 - corpus callosum 124
 - cortex 124
 - thickness 125, 127
 - tic severity correlation 124
 - cortico-basal ganglia circuits 129
 - cortico-striato-thalamo-cortical loops 124
 - dysfunction 122–4, 129
 - tic expression 128
 - diffusion tensor imaging 124, 126
 - dopaminergic transmission
 - abnormality 124, 129
 - endophenotypes 130
 - functional neuroimaging
 - biofeedback 130
 - brain abnormality mapping 124–9
 - GABAergic binding decrease 129
 - genetics 122
 - globus pallidus 124
 - gray matter abnormalities 127
 - neurotransmission abnormalities 129
 - obsessive–compulsive disorder 122, 124, 128–9
 - pathophysiology 122–4
 - phenotypic expression 122
 - prefrontal cortex 128
 - psychiatric disorders 122, 124–9
 - regions of interest 125
 - resting-state fMRI 129
 - sensorimotor networks 128
 - serotonergic neurotransmission 129
 - striatum 124
 - structural neuroimaging 124
 - tics 121–2, 124, 128–9
 - expression 128
 - severity correlation with brain changes 124
 - suppression 128
 - volume measurement 125
 - voxel-based morphometry 125
 - white matter 124, 128
 - glial cell-derived neurotrophic factors 265
 - globular glial tauopathy 162–3
 - globus pallidus (GP)
 - Gilles de la Tourette syndrome 124
 - Huntington's disease 106
 - iron deposition 248–9
 - globus pallidus, external (GPe) 96
 - globus pallidus, internal (GPi) 96
 - deep brain stimulation 95
 - consensus target coordinates 97, 97
 - dystonia 95
 - MRI sequences for visualization 97
 - Parkinson's disease 95
 - glucose metabolism
 - essential tremor 240
 - spinocerebellar ataxia 2 218
 - spinocerebellar ataxia 3 219
 - glutamate
 - ataxia with oculomotor apraxia type 2 211
 - Parkinson's disease 232
 - glutamine, Parkinson's disease 232
 - glutathione, Parkinson's disease 233
 - GM₂ gangliosidosis, late-onset 205
 - gradient echo (GRE) pulse sequences, susceptibility-weighted imaging 2
 - graph theory analysis 87
 - gray matter
 - dystonia 141–2
 - Gilles de la Tourette syndrome 127
 - gray matter atrophy
 - Alzheimer's disease 156
 - cerebrotendinous xanthomatosis 212
 - corticobasal degeneration 154, 156, 157
 - Huntington's disease 110
 - MAPT* gene mutations 159
 - progressive supranuclear palsy syndrome 151
 - hand dystonia 134–5, 136
 - fMRI 135
 - hemichorea 253, 256
 - hemosiderin 14
 - hepatolenticular syndrome 250
 - acquired 251
 - non-Wilsonian 250–1
 - herpetic viral infections 260–1
 - hippocampus
 - familial *MAPT* mutations 160
 - Gilles de la Tourette syndrome 124
 - Parkinson's disease
 - cognitive impairment 79
 - volume 48–9, 52
 - hot cross bun sign 37, 169, 170, 252–3, 254
 - false-positive 254
 - human connectome project, diffusion tensor imaging 8
 - hummingbird sign 36, 36, 150, 150, 252, 253
 - Huntingtin gene 106
 - huntingtin protein 106
 - Huntington's disease 106–17
 - activation foci from T-minus-C comparison 112
 - apparent diffusion coefficients 111
 - biomarkers 106, 111
 - BOLD imaging 111–12
 - brain atrophy 108–9
 - CAG repeats 106, 109
 - caudate nucleus 255
 - cerebral blood flow 112
 - chorea 253
 - coronal MP-RAGE images 107
 - cortical thinning 109
 - diagnosis 106
 - diffusion imaging 111
 - diffusion tensor imaging 111
 - diffusion-weighted imaging 111
 - fMRI 111–12
 - fractional anisotropy 111
 - globus pallidus 106
 - gray matter atrophy 110
 - histology 106
 - ¹H MRS 115–16
 - animal models 116
 - inheritance 106
 - magnetic resonance spectroscopy 113–17
 - MRI findings 107–12
 - multicenter studies 106–7

Index

- Huntington's disease (cont.)
 nuclear imaging 117
 Parkinson's disease differential
 diagnosis 63, 61, 62
 perfusion imaging 111
³¹P MRS 116–17, 117
 putamen 114, 115
 striatal atrophy 109
 substantia nigra 106
 tCr levels 113, 115–16
 thalamic atrophy 109
 tNAA levels 113, 115–16
 volumetric analysis 107–9
 voxel-based morphometry 107–9
 white matter atrophy 110
 hypoparathyroidism 247–8
 hypoxic brain injury, dystonia 257
- impulse control disorders (ICDs),
 Parkinson's disease 73–4, 76–9
- incentive salience, Parkinson's disease
 77–8
- independent component analysis
 (ICA) 86
- infective conditions 260–1
- inferior olivary nucleus
 essential tremor 239–40, 259
 hypertrophy
 Alexander disease 256
 palatal tremor 259
 progressive ataxia with palatal
 tremor 256
- intraoperative MRI 268
- inversion recovery imaging,
 Parkinson's disease 31
- iron
 accumulation in multiple system
 atrophy 21
 brain levels 14–15
 multimodal approaches 17–18
 paramagnetic methods 16–17
 Parkinson's disease 16, 18, 27
 PRIME pulse sequence 16
 relaxation times 17–18
 deposition in basal ganglia 248–50,
 249
 distribution in parkinsonism
 differential diagnosis 20–1
 Parkinson's disease
 accumulation 2
 brain levels 16, 18, 27
 substantia nigra accumulation
 21–2, 29
 proton MRI 15
 quantitation in brain 15–19
 role in brain 14–15
 iron disorders 249–50, 250
 iron imaging
 bound iron 1–2
 Parkinson's disease 1–2, 14–22
 bound iron 1–2
 multimodal approaches 17–18
 quantitation 15–19
 relaxation times 17–18
 susceptibility-based 18–19
 surrogate disease marker 1–2
 susceptibility-weighted imaging 2,
 18–19
 iron-sensitive MRI, multiple system
 atrophy 181, 188–9
- Kufor-Rakeb disease 249–50
- lactate, Parkinson's disease 233–4
- laryngeal dystonia 134, 136–7, 138,
 144
- levodopa, Parkinson's disease 68–9
- Lewy body disorders 44
see also dementia with Lewy bodies
 (DLB)
- locus coeruleus
 iron sequestration 14
 Parkinson's disease 33–4, 34
- Louis-Bar syndrome *see* ataxia
 telangiectasia
- magnetization transfer ratio (MTR)
 2–3
- magnetic resonance spectroscopy
 (MRS) 229–30
 ataxia with oculomotor apraxia
 type 2 211
 ataxia telangiectasia 209
 cerebral mitochondrial function
 measurement 8
 corticobasal degeneration 155
 essential tremor 240–1
 familial MAPT mutations 160
 fragile X tremor/ataxia syndrome
 213
 Friedreich's ataxia 207
¹H 113–15, 229–30, 230
 animal models of Huntington's
 disease 116
 free induction decay 230
 Huntington's disease 115–16
 Huntington's disease 113–17
 multiple system atrophy 193
³¹P 8, 230
 Huntington's disease 116–17
 Parkinson's disease 8, 229–35
 NAA 230–1
 outcome measures 267, 267–8
 potential sources of variability
 234
 progressive supranuclear palsy
 syndrome 153
 quantification 113
- spectral quality 113–15
- spinocerebellar ataxia 1 217
- spinocerebellar ataxia 2 218
- tauopathies 149
- magnetic resonance volumetry
 (MRV), multiple system
 atrophy 179
- magnetization transfer imaging (MTI)
 inversion-prepared protocol 3
 multiple system atrophy 180, 188
 diagnostic accuracy 181
 Parkinson's disease 2–3, 8, 30–1,
 36–8
- manganese, acquired hepatolenticular
 syndrome 251
- MAPT gene *see* familial MAPT
 mutations; microtubule-
 associated protein tau (MAPT)
 gene mutations
- medullar oblongata atrophy,
 spinocerebellar ataxia 2
 217–18
- Meige's syndrome 134, 136, 137, 139,
 144
- metal deposition affecting basal
 ganglia 246–51
- microcephaly 247–8
- microtubule-associated protein tau
 (MAPT) gene mutations 147
 brain atrophy 159
 nuclear medicine 161
 pallidopontonigral degeneration
 variant 148
 parkinsonism 148
 resting-state fMRI 161
 syndrome 148
see also familial MAPT mutations
- midbrain atrophy
 progressive supranuclear palsy 253
 progressive supranuclear palsy
 syndrome 150, 151, 152
- middle cerebellar peduncle atrophy
 fragile X tremor/ataxia syndrome
 212–13
 multiple system atrophy 171–9,
 254
- mitochondrial function, cerebral, MRS
 measurement 8
- mitochondrial protein-associated
 neurodegeneration (MPAN)
 249–50
- molybdenum cofactor deficiency 251,
 252
- mood, fMRI in Parkinson's disease
 72–9
- motivation, dopamine role 73–4
- motivation disorders, cortico-striatal
 system in Parkinson's disease
 76–9

Index

- movement disorders
 - normal/non-specific abnormalities 246
 - see also named conditions and diseases*
- multiple sclerosis 259
 - demyelinating plaques 260
- multiple system atrophy (MSA) 167–98
 - apparent diffusion coefficient 179–80
 - axial mean diffusivity 195
 - brain atrophy 194, 194–5
 - central autonomic degeneration 168–9
 - cerebellar ataxia differential diagnosis 179
 - cerebellar atrophy 170, 190
 - cerebellar variant (MSA-C) 167, 169, 170
 - additional features 168
 - radiological correlation with pathological/clinical data 190
 - voxel-based analysis 192–3
 - clinical trials 196–7
 - corpus callosum 195
 - definition 167
 - diagnosis 167–8
 - diagnostic accuracy of conventional MRI 172
 - diagnostic criteria 167, 168
 - additional features 168
 - differential diagnosis 171
 - Parkinson's disease 179–80, 189
 - diffusion tensor imaging 190–1
 - diffusion-weighted imaging 170, 179–88, 190–1
 - diagnostic accuracy 181
 - putaminal diffusivity 195–6
 - fractional anisotropy 180–7, 191
 - ¹H MRS 193
 - hot cross bun sign 169
 - infratentorial abnormalities 169
 - iron-sensitive MRI 188–9
 - diagnostic accuracy 181
 - limitations of neuroimaging 197–8
 - magnetic resonance volumetry 179
 - magnetization transfer imaging 180, 188
 - diagnostic accuracy 181
 - middle cerebellar peduncle atrophy 254
 - MRI changes 169, 170
 - MRS 193
 - multimodal imaging 189–90
 - neuropathology 168–9
 - olivopontocerebellar atrophy 167–9
 - Parkinson variant (MSA-P) 167, 169
 - additional features 168
 - axial mean diffusivity 188
 - axial MRI 191
 - brain atrophy 192, 194–5
 - ¹H MRS 193
 - iron accumulation in diagnosis 21
 - iron-sensitive MRI 189
 - parkinsonism differential diagnosis 36–8
 - putaminal changes 170
 - radiological correlation with pathological/clinical data 190
 - striatum 196
 - voxel-based analysis 192–3
- Parkinson's disease differential diagnosis 179–80, 189
- planimetry 171–9
 - diagnostic accuracy 176
- pontine atrophy 37, 171–9
- pontocerebellar atrophy 170, 252–3
- progression studies with MRI 193–6
- progressive supranuclear palsy
 - differential diagnosis 171–9, 190
- putamen 195
- putaminal atrophy 190
- putaminal diffusivity 191
- quantitative structural MR
 - techniques 170, 179–90
- radiological correlation with pathological/clinical data 190–1
- regional cerebral atrophy
 - quantitative assessment 171–9
- signal abnormalities 171
- statistical parametric mapping 194–5
- striatonigral degeneration 167–9
- structural MRI 169–71
- volumetry 179
 - diagnostic accuracy 176
- voxel-based morphometry 191–5
 - diagnostic accuracy 176
- musician's dystonia 134, 135, 137–8, 138
- myelin measurement in Parkinson's disease 30
- myoclonus, POLG gene mutations 256–8
- myo*-inositol
 - Alzheimer's disease 232
 - Parkinson's disease 232
- N*-acetylaspartate (NAA)
 - ataxia with oculomotor apraxia type 2 211
 - ataxia telangiectasia 209
 - corticobasal degeneration 155
 - essential tremor 240–1
 - familial *MAPT* mutations 160
 - fragile X tremor/ataxia syndrome 213
 - multiple system atrophy 193
 - Parkinson's disease 230–1, 267
 - progressive supranuclear palsy syndrome 153
 - spinocerebellar ataxia 1 217
- N*-acetylaspartate and *N*-acetylaspartyl glutamate (tNAA)
 - Huntington's disease 113, 115–16
 - Parkinson's disease 230–1
- neuroferritinopathy 249–50
- neuromelanin 31
 - iron binding 14–15
 - Parkinson's disease 14, 27
- neuronal brain iron accumulation syndromes (NBIA) 249–50
- Niemann–Pick disease, type C 163, 205
- non-heme iron, brain content 14
- NPC1 and NCP2 proteins 163
- nuclear medicine
 - cerebrotendinous xanthomatosis 212
 - corticobasal degeneration 155–6, 156
 - familial *MAPT* mutations 161, 161–2
 - Huntington's disease 117
 - Parkinson's disease 264
 - progressive supranuclear palsy syndrome 153, 153–4
 - spinocerebellar ataxia 3 219
 - tauopathies 149
- obsessive–compulsive disorder, Gilles de la Tourette syndrome 122, 124, 128–9
- oculomotor ataxia 209
- olivary nucleus *see* inferior olivary nucleus
- olivopontocerebellar atrophy (OPCA)
 - multiple system atrophy 167–9
 - spinocerebellar ataxia 1 213–16
- orofacial dystonia 136, 137, 139
- overmedication hypothesis, Parkinson's disease
 - cognitive impairment 76
 - motivation disorders 76
- pallidopontonigral degeneration (PPND) 148
- pantothenate kinase-associated neurodegeneration (PKAN) 249–50, 250
- parkinsonism
 - asymmetrical 253
 - clinical applications of neuroimaging 252–3

Index

- parkinsonism (cont.)
 - differential diagnosis 36–8
 - iron distribution 20–1
 - with hydrocephalus 252
 - iron sequestration in substantia nigra 21
 - MAPT* gene mutations 148
 - multiple system atrophy
 - differential diagnosis 36–8
 - iron accumulation in diagnosis 21
 - POLG* gene mutations 256–8
 - pontocerebellar atrophy 252–3
 - postencephalitic 163
 - progressive supranuclear palsy
 - differential diagnosis 36
 - tau protein 20–1
 - vascular 252
- parkinsonism index in MRI 151
- parkinson-plus disorders 252
- Parkinson's disease 1–9
 - acquisition techniques 26–7
 - akinesia 89
 - akinesia-rigidity type 67
 - altered functional connectivity 88
 - anatomical connectivity assessment 30–1
 - animal models 4
 - apathy 73–4
 - resting-state fMRI 89–90
 - apraxia neuronal correlates 67
 - arterial spin labeling 268
 - ascorbate 233
 - ATP 234
 - basal ganglia 170, 233
 - biofeedback training 69
 - biomarkers of disease progression 264
 - BOLD signal 8, 31
 - complex hand movements 62
 - dopaminergic medication effects 68–9
 - fMRI 74
 - outcome measures 266
 - resting-state 84
 - sequential finger movements 65
 - supplementary motor area 57–60, 64, 68–9
 - treatment effects 68–9
- bradykinesia 66
- brain atrophy 194
- brainstem 170, 229
- cerebellar volume 48
- cerebello-thalamo-cortical circuit 67
- choline 231
- clinical applications of MRI 8–9
- clinical trials 264–8
 - databases for multicenter imaging studies 268
 - outcome measures 264–5
 - potential MRI measures 265–7
- cognitive impairment 44–51, 72
 - age effects 49
 - amygdala 49
 - cognitive measure correlation 47
 - cognitive spectrum 46
 - cortical atrophy 46, 50
 - cortico-striatal network function 74–6
 - deactivated brain regions 79
 - default mode network 79
 - entorhinal cortex 49, 52
 - global MRI measures 48
 - hippocampal volume 48–9
 - hippocampus 79
 - longitudinal studies 49–50
 - overmedication hypothesis 76
 - resting-state fMRI 89–90
 - substantia innominata 49
 - treated patients 46
 - white matter changes 51
- cognitive spectrum 46
- cognitively normal (PD-CN) 45–6
 - brain regions affected 52
- cortical atrophy 46, 48
- cortical hyperactivation 66
- cortical lesions 34–5
- cortical thickness measurement 28–9, 45
 - cognitive impairment 47–8
- cortico-striatal system 72–3
 - cognitive impairment 74–6
 - incentive salience 77–8
 - motivation disorders 76–9
 - reward processing 77
 - risk-taking 78
- cortico-striato-pallido-thalamo-cortical circuit model 88
- creatine 231
- databases for multicenter imaging studies 268
- deactivated brain regions 79
- deep brain stimulation 8, 19–20
 - fMRI 69
 - subthalamic nucleus 9, 95
- default mode network 79
- task performance 90
- deformation-based morphometry 45, 48
- dementia 44, 72, 252
- depression 35
 - resting-state fMRI 89–90
- differential diagnosis 235
- diffusion changes 32, 36–8, 45
- diffusion tensor imaging 7–8, 30, 36–8, 45
 - cognitive impairment 51
 - iron levels 17, 18
 - outcome measures 265–6
- diffusion-weighted imaging 30, 36–8, 45
- dopamine deficiency 72–4
 - cortical activation 75
- dopamine transporter imaging 242
- dopaminergic medication
 - BOLD signal effects 68–9
 - cortico-striatal connectivity 89
 - overmedication hypothesis 76
 - reward-based learning 77
- dopaminergic neuron loss 57
- dopaminergic nigrostriatal neurons 233, 242
 - degeneration 232
 - essential tremor distinction 242
 - loss 57
 - nuclear imaging 264
- early 45–6
- essential tremor differential diagnosis 242–3
- executive dysfunction 72, 74–6
- extranigral pathology 26, 33–4
- ferritin brain content 15–16
- FLAIR imaging 45
- fMRI 57–69
 - BOLD signal 74
 - cognition and mood 72–9
 - complex hand movements 62–5
 - hand movement correlates 57–62
 - methods 74
 - motor symptom correlates 65–8
 - outcome measures 266–7
- focal atrophy 46
- fractional anisotropy 7, 7, 11, 45
 - cognitive impairment 51
 - iron levels 17
 - outcome measures 265–6
- freezing of gait 35, 67–8
 - resting-state fMRI 89
- frontostriatal syndrome 72
- functional connectivity assessment 31, 35
- functional imaging 36–8
- functional network loss 88
- GABA 232–3
- gait 67–8
- gene vector delivery 268
- glutamate/glutamine 232
- glutathione 233
- hand movements
 - complex 62–5
 - dual tasks 62–4
 - fMRI correlates 57–62
 - sequential finger movements 65
- hippocampus
 - cognitive impairment 79
 - volume 48–9, 52
- ¹H MRS 193, 231, 234

Index

- outcome measures 267–8
- Huntington's disease differential
 - diagnosis 61, 62, 63
- idiopathic 252
- impulse control disorders 73–4, 76–9
- incentive salience 77–8
- incidence 1
- incident 45–6
- internal globus pallidus, deep brain stimulation 95
- inversion recovery imaging 31
- iron binding to neuromelanin 14, 27
- iron imaging 1–2, 2, 14–22
 - bound iron 1–2
 - brain levels 16, 27
 - multimodal approaches 17–18
 - quantitation 15–19
 - relaxation times 17–18
 - substantia nigra 29
 - susceptibility-based 18–19
- iron sequestration in substantia nigra 14, 21–2
- isolated action tremor 243
- lactate 233–4
- locus coeruleus 33–4, 34
- magnetization transfer imaging 2–3, 8, 30–1, 36–8
- manual segmentation of regions of interest 27, 45
- markers for therapeutic interventions 264
- mild cognitive impairment (PD-MCI) 45–6
 - brain regions affected 52
 - cortical atrophy 46, 48
 - global MRI measures 48
 - subgroups 47
- motor system hyperactivation 65–6
- MRS 8, 229–35
 - outcome measures 267, 267–8
- multimodal imaging 235
- multiple system atrophy differential diagnosis 179–80, 189
- myelin measurement 30
- myo*-inositol 232
- N*-acetylaspartate 230–1, 267
- neuromelanin 31
- neuronal network connectivity 60–1
- nuclear medicine 264
- phosphocreatine 231
- ³¹P MRS 231, 234
- pontine reticular formation 34
- quantitative MRI 29–30
- quantitative susceptibility mapping 22, 23
- radial distance mapping 48
- rapid eye movement sleep
 - behavioral disorder 34
- rate maps 6
- regions of interest 27
- relaxation times 29–30, 32, 36–8
 - iron levels 17–18
- relaxations along a fictitious field 4–5
- resting-state fMRI 8, 84–9
 - akinesia 89
 - biomarker potential 90
 - cognitive assessment 89–90
 - dopaminergic treatment 89
 - freezing of gait 89
 - substantia nigra 32
 - tremor 89
- reward prediction error signal 73
- reward processing 77
- risk-taking 78
- rotating frame relaxation methods 3–4
- 7T MRI platforms 1–2, 9, 22, 33
 - substantia nigra 34
- statistical parametric mapping 7, 6
- striatal-thalamo-cortical circuit 67
- structural imaging 26–9, 36–8
- subcortical region 10
- substantia nigra 233
 - dopaminergic projection neuron loss 26
 - imaging 5, 20, 29, 31, 31–3, 32, 33
 - iron sequestration 14, 21–2
 - 7T MRI platforms 34
- subthalamic nucleus 21, 88
 - deep brain stimulation 9, 95
 - resting-state fMRI 89
- supplementary motor area 57
 - akinesia 89
 - BOLD signal 57–60, 64, 68–9
 - hand movements 64
 - resting-state fMRI 89
- surrogate biomarkers 1
- susceptibility-weighted imaging 2, 18–19
- T₂ imaging 1
- 3T MRI platforms 22
- time constants 5
- tractography 30–3, 268
- transverse relaxation 17
- tremor 35
 - resting-state fMRI 89
- visual hallucinations 35
- volumetric measurements 6–7
- voxel-based morphometry 6–7, 28–9, 45, 50
 - cognitive impairment 46–7
- white matter lesions 45, 51, 265–6
- Parkinson's disease with dementia (PDD) 44, 252
- brain regions affected 52
- cognitive impairment 44
- cortical atrophy 46, 48
- global MRI measures 48
- hippocampal volume 48–9
- structural imaging 48
- partially refocused interleaved multiple-echo (PRIME) pulse sequence 16
- PCfdr network 86–7
- penguin sign 36, 150, 150
- phosphocreatine (PCr)
 - Parkinson's disease 231
 - see also* creatine and phosphocreatine (tCr)
- phospholipase A2-associated neurodegeneration (PLAN) 249–50
- phytanic acid 211
- phytanoyl-CoA-hydroxylase gene 211
- Pick's disease 147–8
 - cortical atrophy 162
 - neuroimaging 162
 - pathological characteristics 148
- planimetry, multiple system atrophy 171–9
- polymerase gamma (*POLG*) gene mutations 256–8, 259
- pontine atrophy
 - multiple system atrophy 37, 171–9
 - spinocerebellar ataxia 2 217–18
- pontine reticular formation 34
- pontocerebellar atrophy
 - multiple system atrophy 170, 252–3
- parkinsonism 252–3
- spinocerebellar ataxia 1 217
- spinocerebellar ataxia 3 218–19
- spinocerebellar ataxia 7 223
- positron emission tomography (PET)
 - corticobasal degeneration 155–6, 156
 - essential tremor 239–40
 - familial *MAPT* mutations 161–2
 - progressive supranuclear palsy syndrome 153, 153
- postencephalitic parkinsonism (PEP) 163, 261
- post-infective disorders 261
- prefrontal cortex, Gilles de la Tourette syndrome 128
- premotor cortex atrophy, corticobasal syndrome 154
- primary progressive apraxia of speech (PPAOS) 147, 157, 158
 - atrophy distribution 149
- prion diseases 259
 - see also* Creutzfeldt–Jakob disease
- progressive ataxia with palatal tremor (PAPT) 256, 258

Index

- progressive supranuclear palsy (PSP)
147–8
brain atrophy 194
brainstem atrophy 158, 253
imaging in pathologically confirmed
36, 157–8
midbrain atrophy 253
multiple system atrophy differential
diagnosis 171–9, 190
parkinsonism differential diagnosis 36
tau protein 20–1
pathological characteristics 148
voxel-based morphometry 37
- progressive supranuclear palsy
corticobasal syndrome hybrid
149, 156
- progressive supranuclear palsy
syndrome (PSPS) 147–8,
150–4
atrophy distribution 149
brainstem 150
diffusion tensor imaging 152–3
gray matter atrophy 151
midbrain atrophy 150, 151
MRS 153
nuclear medicine 153, 153–4
resting-state fMRI 154
striatal dopamine binding 153
structural MRI 150–2
superior cerebellar peduncle
atrophy 150–1, 151, 154
white matter atrophy 151
white matter tract degeneration 152,
152–3
- proton MRI 15
- putamen
Huntington's disease 114, 115
multiple system atrophy 190, 195
diffusivity 191
Parkinson variant (MSA-P) 170
- quantitative susceptibility mapping
(QSM), Parkinson's disease
22, 23
- radial distance mapping, Parkinson's
disease 48
- rapid eye movement sleep behavioral
disorder (RBD)
idiopathic 34
Parkinson's disease 34
pontine reticular formation 34
voxel-based morphometry 6
- red nucleus, iron deposition 248–9
- Refsum's disease 205, 211
dentate nucleus 211
- relaxation times, Parkinson's disease
29–30, 32, 36–8
iron levels 17–18
- relaxations along a fictitious field
(RAFF), Parkinson's disease
4–5
- resting-state fMRI (rs-fMRI)
advantages 87–8
causal methods 86–7
dynamic Bayesian networks 86–7
dysfunction markers 87–8
dystonia 141
familial *MAPT* mutations 160–1,
161
functional connectivity 85–7
Gilles de la Tourette syndrome 129
graph theory analysis 87
group network studies 87
independent component analysis 86
methodologies 85–7
Parkinson's disease 8, 84–9
akinesia 89
biomarker potential 90
cognitive assessment 89–90
dopaminergic treatment 89
freezing of gait 89
substantia nigra 32
tremor 89
patient population diversity 87
PCfdr network 86–7
pre-surgical brain mapping 88
progressive supranuclear palsy
syndrome 154
regions of interest 86
resting-state networks 84–5
seed-based method 86
tauopathies 149
therapeutic intervention
changes 88
- resting-state networks (RSN) 84
anatomy 84–5
dysfunction markers 87–8
pre-surgical brain mapping 88
therapeutic intervention changes 88
- reward prediction error (RPE) signal
73, 73–4, 77
- reward processing, Parkinson's disease
77
- Richardson's syndrome
see progressive supranuclear
palsy (PSP)
- risk-taking, Parkinson's disease 78
- rotating frame relaxation constants
($R_{1\rho}$ and $R_{2\rho}$) 3–4
- rotating frame relaxation methods
adiabatic pulses 3–4
Parkinson's disease 3–4
- salience network, connectivity in
familial *MAPT* mutations 160
- senataxin (*SETX*) gene 210
- sensorimotor network (SMN) 85
- sensory axonal neuropathy with
dysarthria and
ophthalmoplegia 205
- serotonergic neurotransmission, Gilles
de la Tourette syndrome 129
- 7T MRI platforms
deep brain stimulation 98, 100–2
 ^1H MRS in Huntington's disease
115
Parkinson's disease 1–2, 9, 22, 33
substantia nigra 34
potential problems 101–2
registration to 1.5T MRI 102
signal-to-noise ratio 100–1
- single-photon emission tomography
(SPECT)
corticobasal degeneration 155–6
familial *MAPT* mutations 161–2
progressive supranuclear palsy
syndrome 153
- somatosensory system, dystonia
138–41
- Spatial Pattern of Abnormalities for
Recognition (SPARE-PDD) 48
- spinal cord atrophy, spinocerebellar
ataxia 2 217–18
- spinocerebellar ataxias, autosomal
dominant 213–23, 214
myo-inositol 232
spinocerebellar ataxia 1 213–17,
214, 215
brain volume 216
clinical signs 213
neuroimaging 213–17
neuronal loss 217
spinocerebellar ataxia 2 214, 217–18
clinical signs 217
neuroimaging 217–18
voxel-based morphometry 218
spinocerebellar ataxia 3 214,
218–19
clinical signs 218
neuroimaging 218–19
spinocerebellar ataxia 6 214, 219–20
spinocerebellar ataxia 7 214, 219,
220, 220–3
spinocerebellar ataxia 17 214, 223
function/connectivity 222–3
longitudinal imaging 221
voxel-based morphometry 221
- statistical parametric mapping (SPM),
multiple system atrophy
194–5
- stereotactic neurosurgery 94–5
see also deep brain stimulation
(DBS) surgery
- sterol 27-hydroxylase 211
- striatonigral degeneration, multiple
system atrophy 167–9

Index

- striatum
 - atrophy in progressive supranuclear palsy syndrome 151–2
 - Gilles de la Tourette syndrome 124
 - multiple system atrophy 196
- structural MRI
 - corticobasal syndrome 154
 - familial *MAPT* mutations 158–60
 - multiple system atrophy 169–71
 - Parkinson's disease outcome measures 265
 - progressive supranuclear palsy syndrome 150–2
 - tauopathies 148–9
- subacute sclerosing panencephalitis 163
- substantia nigra
 - anatomy 28
 - diffusion tensor imaging 266
 - Huntington's disease 106
 - iron deposition 248–9
 - Parkinson's disease 233
 - imaging 5, 20, 29, 31–3, 31–3
 - iron sequestration 14, 21–2
 - 7T MRI platforms 34
 - susceptibility-weighted imaging 100
 - tractography 31
- substantia nigra pars compacta (SNc) 31
 - high-field imaging 17
 - iron sequestration
 - Alzheimer's disease 21
 - parkinsonism 21
 - Parkinson's disease 14, 21–2
- substantia nigra pars reticulata (SNr) 31
- subthalamic nucleus (STN)
 - deep brain stimulation
 - consensus target coordinates 97, 97
 - MRI sequences for visualization 97
 - Parkinson's disease 19–20, 95
 - Parkinson's disease 9, 21, 88
 - deep brain stimulation 19–20, 95
 - glutamatergic projection alteration 232
 - resting-state fMRI 89
 - susceptibility-weighted imaging 100
- superior cerebellar peduncle
 - atrophy
 - progressive supranuclear palsy syndrome 150–1, 151, 154
 - spinocerebellar ataxia 3 219
 - Friedreich's ataxia 207
- supplementary motor area (SMA), Parkinson's disease 57
 - akinesia 89
 - BOLD signal 57–60, 64, 68–9
 - hand movements 64
 - resting-state fMRI 89
- susceptibility-weighted imaging (SWI)
 - gradient echo (GRE) pulse sequences 2
 - iron imaging 2, 18–19
 - Parkinson's disease 2
 - iron levels 18–19
 - substantia nigra 100
 - subthalamic nucleus 100
- Sydenham's chorea 261
- tangle-dominant dementia 163–4
- TATA-binding protein 223
- tau protein 20–1
- tauopathies 147–64
 - clinical syndromes 147–8
 - diffusion tensor imaging 149
 - magnetic resonance spectroscopy 149
 - neuroimaging 148–64
 - nuclear medicine 149
 - resting-state fMRI 149
 - structural MRI 148–9
 - see also named conditions and disorders*
- thalamic nuclei 98
- thalamus, fiber pathways 101
- 3T MRI platforms
 - ¹H MRS in Huntington's disease 115
 - Parkinson's disease 22
- Tourette syndrome *see* Gilles de la Tourette syndrome
- toxoplasmosis 260, 262
- tractography
 - Parkinson's disease 30–3, 268
 - substantia nigra 31
- transverse relaxation, Parkinson's disease 17
- tremor
 - acute disseminated encephalomyelitis 259
 - deep brain stimulation of ventral intermediate nucleus 95–6
 - isolated action 243
 - multiple sclerosis 259
 - Parkinson's disease 35
 - resting-state fMRI 89
 - ventral intermediate nucleus, deep brain stimulation 95–6
 - see also* essential tremor
- Unified Parkinson's Disease Rating Scale 264–5
- ventral intermediate nucleus (VIM), deep brain stimulation
 - consensus target coordinates 97, 97
 - MRI sequences for visualization 97
 - tremor 95–6
- visual hallucinations, Parkinson's disease 35
- visual network (VIN) 85
- vitamin E deficiency 211
- von Economo disease
 - see* postencephalitic parkinsonism (PEP)
- voxel-based morphometry (VBM)
 - dystonia 141–2, 144
 - essential tremor 241
 - Friedreich's ataxia 207
 - Gilles de la Tourette syndrome 125
 - Huntington's disease 107–9
 - multiple system atrophy 191–5
 - diagnostic accuracy 176
 - Parkinson's disease 6–7, 28–9, 45, 50
 - cognitive impairment 46–7
 - progressive supranuclear palsy 37
 - spinocerebellar ataxia 2 218
 - spinocerebellar ataxia 17 221
- white matter atrophy
 - cerebrotendinous xanthomatosis 212
 - corticobasal degeneration 154
 - Huntington's disease 110
 - MAPT* gene mutations 159
 - progressive supranuclear palsy syndrome 151
- white matter lesions
 - ataxia telangiectasia 209
 - cerebrotendinous xanthomatosis 212
 - dystonia 143–4
 - fragile X tremor/ataxia syndrome 212
 - Parkinson's disease 45, 51, 265–6
- white matter tract degeneration
 - corticobasal degeneration 154–5
 - familial *MAPT* mutations 160
 - progressive supranuclear palsy syndrome 152, 152–3
- Wilson's disease 250
- writer's cramp 134, 139, 140, 142